Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Lysoclear
AddedFeb 17, 2024
UpdatedJun 18, 2026
Lysoclear

Lysoclear

Lysoclear, Inc.: Developing enzyme therapies for age-related and Stargardt's macular degeneration.

HQ
LaFayette, NY, US
Founded
2016
Overview
Compare
Fundraising
Employees
Website

Lysoclear, Inc. was founded with the mission to develop enzyme therapies targeting eye diseases, specifically atrophic "dry" age-related macular degeneration (AMD) and Stargardt’s macular degeneration (SMD). As a pre-clinical company within the Ichor Therapeutics portfolio, Lysoclear focuses on innovative treatments to address the gradual loss of retinal pigmented epithelial cells in the macula, which is crucial for central vision.

Notable affiliates include Ichor Therapeutics, a prominent entity in the biotech industry. Lysoclear has made significant strides in pre-clinical development, positioning itself as a pioneering force in enzyme therapy for ocular diseases. The company's work has the potential to significantly impact the treatment landscape for AMD and SMD, offering hope to millions affected by these degenerative conditions.

Lysoclear - Similar Companies

Macuclear logo

Macuclear

Lysosomal Therapeutics logo

Lysosomal Therapeutics

lysosomaltx.com

TearClear logo

TearClear

tearclear.com

EnClear Therapies logo

EnClear Therapies

ExoLytics logo

ExoLytics

exolytics.com

Qlaris Bio logo

Qlaris Bio

qlaris.bio

EyeCyte logo

EyeCyte

eyecyte.com

Clearside Biomedical logo

Clearside Biomedical

clearsidebio.com

EnzymeRx logo

EnzymeRx

i-Lumen Scientific logo

i-Lumen Scientific

i-lumen.com

Oculogenex logo

Oculogenex

oculogenex.com

Aldeyra Therapeutics logo

Aldeyra Therapeutics

Seeing Medicines logo

Seeing Medicines

Endlyz Therapeutics logo

Endlyz Therapeutics

Optherion logo

Optherion

optherion.com

Lysoclear - Quick Facts

Who are Lysoclear's competitors?

Companies similar to Lysoclear include Macuclear, Lysosomal Therapeutics, TearClear and EnClear Therapies.

When was Lysoclear founded?

Lysoclear was founded in 2016.

Where is Lysoclear's headquarters located?

Lysoclear's headquarters is located in LaFayette, NY, US.

When was Lysoclear's last funding round?

Lysoclear's most recent funding round was for $3M (USD) in December 2018.

How much has Lysoclear raised to-date?

As of Dec 19, 2018, Lysoclear has raised a total of $3M (USD).

How many employees does Lysoclear have?

Lysoclear has 5 employees as of Feb 5, 2024.

Lysoclear - Classification

Technology
  • Biotech
Geographic Exposure
  • Global
Main Product
  • Enzyme Therapies
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 4 more industry codes
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified